Diabetic Nephropathy Market 2022
Global Diabetic Nephropathy Market will reach $3.14 billion in 2022.
According to a new market report published by Persistence Market Research “Global Market Study on Diabetic Nephropathy Market – Asia to Witness Highest Growth by 2022,”.The global diabetic nephropathy market was valued at USD 2,262.2 million in 2016 and is expected to grow at a CAGR of 5.6% from 2016 to 2022, to reach an expected value of USD 3,145.9 million in 2022.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3594
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Globally, the diabetic nephropathy market is witnessing significant growth due to increasing prevalence of diabetes and obesity in different regions of the world.
In addition, increasing R&D investments in drug discovery and development and raising awareness about diabetes and kidney-related disorders are also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market.
Some of the major players in the diabetic nephropathy market:
- Novartis AG, Merck & Co., Inc.
- Pfizer, Inc.
- Abbott Laboratories.
- Sanofi.
- Eli Lilly.
- Company.
- Reata Pharmaceuticals, Inc.
- Bayer AG, AbbVie, Inc.
- Mitsubishi Tanabe Pharma Corporation.
- Other
In North America, various government programs are spreading awareness about diabetes and related renal complications. For instance, the National Kidney Disease Education Program, one of the major programs organized by the U.S. government, for increasing awareness about the various kidney diseases. In addition, the number of diabetic patients are also increasing in the region; according to the SciELO Public Health, approximately 35 million people were affected with diabetes mellitus in 2000 and this number is expected to reach 64 million by 2025 in North America.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/3594
In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalence of diabetes in the various part of Europe is boosting the growth of the European diabetic nephropathy market. According to IDF, approximately 55.4 million people had diabetes in 2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to the IDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in 2010 and is expected to reach USD 124.6 billion by 2030 in Europe.
Asia represents the fastest growing region in the diabetic nephropathy market due to the rise in a diabetic population in various countries such as Japan and the Southeast Asian countries. According to the International Diabetes Federation (IDF), developing countries, such as India and China, are expected to have the highest number of diabetes mellitus patients compared to developed countries, such as the U.S. and Germany.
The global diabetic nephropathy market is segmented as follows:
Diabetic nephropathy market, by model of treatment
- Disease Modifying Therapies
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Diuretics
- Calcium Channel Blockers
- Renin Inhibitors
- Connective Tissue Growth Factor Inhibitors
- Antioxidant Inflammation Modulator
- Monocyte Chemoattractant Proteins Inhibitor
- Endothelin-A Receptor Antagonist
- G Protein-Coupled Receptors
Key geographies evaluated in this report are:
North America – U.S, Canada
Europe – France, Germany, Italy, Spain, and the UK, Eastern Europe, CIS
APAC – China, India, Japan, Australia, Others
Latin America – Argentina, Brazil, Others
Access Full Report@ https://www.persistencemarketresearch.com/checkout/3594
Key Questions Answered in This Report.
- What will the Market growth rate in Future?
- What are the key factors driving the global Market?
- Who are the key manufacturers in Market space?
- What are the opportunities and threats faced by the vendors in the global industry?
- What are sales, revenue, and price analysis by regions of industry?
About us:
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]